

- (51) International Patent Classification:

A61K 31/712 (2006.01)
- (21) International Application Number:

PCT/US2024/032131
- (22) International Filing Date:

31 May 2024 (31.05.2024)
- (25) Filing Language:

English
- (26) Publication Language:

English
- (30) Priority Data:

63/505,333 31 May 2023 (31.05.2023) US
- (71) Applicant: STOKES THERAPEUTICS, INC. [US/US];

45 Wiggins Avenue, Bedford, Massachusetts 01730 (US).
- (72) Inventors: AZNAREZ, Isabel; c/o Stokes Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730 (US). VENKATESH, Aditya; c/o Stokes Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730 (US). RAVIPATY, Shobha; c/o Stokes Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730 (US). MEENA, Meena; c/o Stokes Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730 (US). PETERS, David Grant; c/o Stokes Therapeutics, Inc., 45 Wiggins Avenue, Bedford, Massachusetts 01730 (US).
- (74) Agent: NIP, Lisa et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: OPA1 ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES




FIG. 2A

(57) Abstract: Alternative splicing events in genes can lead to nonproductive mRNA transcripts which in turn can lead to aberrant protein expression, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Such therapeutic agents can be used to treat a condition or disease caused by protein deficiency and/or mitochondrial function deficit.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*